Evidence map›Paper›PMID 37663085›Full record

ArticleThe World Allergy Organization journal2023

Comparison of recent anaphylaxis diagnostic criteria in real life: Can more patients be diagnosed as having anaphylaxis?

Osman Ozan Yeğit, Ayşe Feyza Aslan, Raif Coşkun, Pelin Karadağ, İlkim Deniz Toprak, Ali Can, Nida Öztop, Semra Demir, Derya Ünal, Müge Olgaç and 1 more

Open access · goldAbstract read
In one paragraph

Article in The World Allergy Organization journal, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.7field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Drug-Induced Anaphylaxis: National Database Analysis.Pharmaceuticals (Basel, Switzerland) · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Osman Ozan YeğitDepartment of Internal Medicine, Division of Immunology and Allergy, Istanbul University, Istanbul, Türkiye.
Ayşe Feyza AslanDepartment of Internal Medicine, Division of Immunology and Allergy, Istanbul University, Istanbul, Türkiye.
Raif CoşkunAdult Immunology and Allergy Clinic, Prof. Dr. Cemil Taşcıoğlu City Hospital, Istanbul, Türkiye.
Pelin KaradağDepartment of Internal Medicine, Division of Immunology and Allergy, Istanbul University, Istanbul, Türkiye.
İlkim Deniz ToprakDepartment of Internal Medicine, Division of Immunology and Allergy, Istanbul University, Istanbul, Türkiye.
Ali CanDepartment of Internal Medicine, Division of Immunology and Allergy, Istanbul University, Istanbul, Türkiye.
Nida ÖztopDepartment of Internal Medicine, Division of Immunology and Allergy, Istanbul University, Istanbul, Türkiye.
Semra DemirDepartment of Internal Medicine, Division of Immunology and Allergy, Istanbul University, Istanbul, Türkiye.
Derya ÜnalDepartment of Internal Medicine, Division of Immunology and Allergy, Istanbul University, Istanbul, Türkiye.
Müge OlgaçAdult Immunology and Allergy Clinic, Şişli Hamidiye Etfal Education and Research Hospital, Istanbul, Türkiye.
Aslı GelincikDepartment of Internal Medicine, Division of Immunology and Allergy, Istanbul University, Istanbul, Türkiye.
Istanbul University · TRŞişli Etfal Eğitim ve Araştırma Hastanesi · TR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: In 2020, World Allergy Organization (WAO) updated their diagnostic criteria for anaphylaxis, which differed as a result from the National Institute of Allergy and Infectious Diseases/Food Allergy and Anaphylaxis Network (NIAID/FAAN) criteria which were still used in the 2021 update of the European Academy of Allergy and Clinical Immunology (EAACI) anaphylaxis guideline. Our aim was to evaluate and to compare both diagnostic criteria and attempt to identify factors affecting severity of anaphylaxis. Methods: The medical records of the patients who were evaluated with suspected anaphylaxis at 3 medical centers in Türkiye between 2014 and 2021, and underwent a detailed diagnostic work-up, were analyzed retrospectively. Diagnosis of anaphylaxis was evaluated based on the WAO 2020 and EAACI 2021 and NIAID/FAAN diagnostic criteria. The severity of anaphylaxis was determined according to the WAO systemic allergic reaction grading system. Grade 5 anaphylaxis was defined as having respiratory failure, collapse/hypotension, loss of consciousness. Patients' demographic and clinical characteristics were further analyzed depending on the severity of the reaction. Results: One thousand and six patients were evaluated and 232 patients without a convincing diagnosis of anaphylaxis were excluded from the study. The remaining 774 patients (70.6% female, median [Inter quartile range (IQR) 25-75] age: 42 [33-52]) were included for further examination. Anaphylaxis was diagnosed in 729 (94.2%) patients meeting both criteria whereas 35 patients (4.5%) with isolated laryngeal involvement and 10 (1.3%) patients with isolated respiratory involvement were only diagnosed according to the WAO 2020 criteria. Twenty-three patients (3.0%) had a diagnosis of indolent systemic mastocytosis. Mastocytosis was related to grade 5 anaphylaxis [p = 0.022, OR (CI) = 2.9 (1.1-7.6)]. Venom allergy was a risk factor for grade 5 anaphylaxis among those for whom an eliciting allergen could be determined [p = 0.03, OR (CI) = 2.7 (1.1-6.8)]. For drug induced anaphylaxis, parenteral route of drug administration and proton pump inhibitor (PPI) allergy were considered as risk factors for grade 5 anaphylaxis [p < 0.001, OR (CI) = 6.5 (2.5-17.0); p = 0.011, OR (CI) = 10.3 (1.6-63.3)]. Conclusion: This multicenter study demonstrated that both criteria identified the majority of patients with anaphylaxis, but the WAO 2020 diagnostic criteria identified an additional 6%. Hymenoptera stings, PPI allergy, parenteral drug administration, and underlying mastocytosis were associated with more severe episodes.

Indexed as

AnaphylaxisDiagnostic criteriaRisk factorsSevere anaphylaxis

Identifiers

PMID37663085
PMCPMC10470287
OpenAlexW4386196157

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.